Anti-Cancer Drugs · 2019 · 15 citations · 9 references
MedicineDermatologyOncologyCutaneous OncologyDermatopathologyImmunotherapyAutoimmune Skin DiseasesCutaneous NeoplasmsImmunopathology Of SkinImmunotherapy For Skin CancerNeoplastic Skin LesionsUveal MelanomaCutaneous BlisteringDermatologic DisordersDermatologic SequelaeHand-foot Skin ReactionImmune Checkpoint Inhibitor TherapyImmune-mediated Adverse EventsImmune-related Skin ToxicityMetastatic Uveal Melanoma
Antibodies directed against programmed death receptor 1 emerged as beneficial immune-checkpoint inhibitor therapy in many different types of cancer. However, programmed death receptor 1 is critical in promoting self-tolerance and the most common toxicities of checkpoint inhibitors are immune-related adverse events. We present a 48-year-old woman affected by metastatic uveal melanoma treated with nivolumab (3 mg/kg every 2 weeks). The patient had no previous history of autoimmune disease or dermatologic conditions. At the fourth month of treatment, on cutaneous examination, she presented multiple whitish vitiligo-like patches on the trunk, axillae, hands and face. Diagnosis of melanoma-associated leukoderma vitiliginous reaction was made. Over the following months, the melanoma-associated leukoderma lesions slowly progressed with cigarette paper-like appearance and indurated texture. A skin biopsy leaded the diagnosis of extragenital lichen sclerosus. To the best of our knowledge, this is the first reported case of extragenital lichen sclerosus on previous melanoma-associated leukoderma lesions related to nivolumab monotherapy. The increase in clinical experience with anti programmed death receptor 1 enhances the knowledge about adverse effects associated with these immunotherapies and allows to compare therapeutic strategies.
9
Igor Puzanov, Adi Diab, K. Abdallah et al. · Journal for ImmunoTherapy of Cancer · 2017 · 2K citations · Full text
Life Sciences, Immunology, Oncology +17
M. Larsabal, A. Marti, C. Jacquemin et al. · Journal of the American Academy of Dermatology · 2017 · 157 citations
Scleroderma Induced by Pembrolizumab: A Case Series
Naiara S. Barbosa, David A. Wetter, Carilyn N. Wieland et al. · Mayo Clinic Proceedings · 2017 · 101 citations · Full text
Scleroderma‐like skin changes induced by checkpoint inhibitor therapy
B Joel Tjarks, Amy M Kerkvliet, Ali Jassim et al. · Journal of Cutaneous Pathology · 2018 · 56 citations
Medicine, Dermatology, Oncology +15